Kate Rochlin
President & Chief Operating Officer IN8Bio
Kate has served as IN8bio’s Chief Operating Officer since December 2021 and previously as their VP, Operations and Innovation. IN8bio is a clinical stage gamma-delta T cell company with programs in Oncology and Autoimmune disease. She has 20+ years of expertise in strategic company development & operations, IP, CMC, and clinical manufacturing of advanced therapies. She was previously the Chief Business Officer at Curadigm, a Cambridge-based spin-out of Nanobiotix focused on lipid nanoparticles for RNA therapeutic bioavailability. Prior, Dr. Rochlin co-founded and served as CSO at Immunovent. Dr. Rochlin earned a Ph.D. in Molecular Biology and Genetics from Weill Cornell Medical College and Sloan Kettering Institute and a BA from the University of Pennsylvania.
Seminars
- What is the remaining first-in-class opportunity for bispecifics/multispecifics in cancer? Where do engagers fit into different lines of treatment and relapsed or resistant patients?
- How are bispecifics/multispecific formats and targets being optimized to expand applications across a breadth of solid tumors beyond blood cancer?
- Understanding how bispecifics/multispecifics can accelerate into clinical trials more quickly in the oncology setting, how this drug modality fits into the broader continuum of care for cancer, and how this translates into remaining market opportunity for cancer
- Developing or repurposing bispecifics/multispecifics for immunology to achieve sustained immune cell depletion and recognizing the different risk-benefit profiles in cancer versus immunology
- Recognizing the higher benchmark for safety data in the immunology/autoimmune disease setting compared to oncology
- Exploring gamma delta T cells as a differentiated immune effector population to overcome limitations associated with classical CD3-based T-cell engagers
- Solving the scarcity issue: Novel TCE design or mechanism to expand gamma-delta T-cells in vivo
- Leveraging preclinical evidence and clinical insight from gamma delta T-cell therapies to inform safety, efficacy, and broader applicability
